Pro-inflammatory Interleukin-18 and Caspase-1 serum levels in liver failure are unaffected by MARS treatment

Digestive and Liver Disease

Volumn 41, Issue 6, 2009, Pages 417-423

  Roth, G A ^a   Faybik, P ^a   Hetz, H ^a   Hacker, S ^a   Ankersmit, H J ^a   Bacher, A ^a   Thalhammer, T ^a   Krenn, C G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute liver failure; Acute on chronic liver failure; Caspase 1; Cytokines; IL 18; MARS

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME;

ACUTE DISEASE; ADULT; AGED; ALBUMIN DIALYSIS; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER FAILURE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CASPASE 1; FEMALE; HUMANS; INTERLEUKIN-18; LIVER FAILURE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SORPTION DETOXIFICATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67349243450     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.09.021     Document Type: Article

References (41)

1. Polson J., and Lee W.M. AASLD position paper: the management of acute liver failure. Hepatology 41 (2005) 1179-1197
2. Rinella M.E., and Sanyal A. Intensive management of hepatic failure. Semin Respir Crit Care Med 27 (2006) 241-261
3. Schmidt L.E., Sorensen V.R., Svendsen L.B., Hansen B.A., and Larsen F.S. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure. Liver Transplant 7 (2001) 1034-1039
4. Schmidt L.E., Wang L.P., Hansen B.A., and Larsen F.S. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transplant 9 (2003) 290-297
5. Sen S., Davies N.A., Mookerjee R.P., Cheshire L.M., Hodges S.J., Williams R., et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transplant 10 (2004) 1109-1119
6. Sen S., Williams R., and Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 100 (2005) 468-475
7. Steiner C., Sen S., Stange J., Williams R., and Jalan R. Binding of bilirubin and bromosulphthalein to albumin: implications for understanding the pathophysiology of liver failure and its management. Liver Transplant 10 (2004) 1531-1538
8. Heemann U., Treichel U., Loock J., Philipp T., Gerken G., Malago M., et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 36 (2002) 949-958
9. Mitzner S.R., Stange J., Klammt S., Risler T., Erley C.M., Bader B.D., et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transplant 6 (2000) 277-286
10. Ambrosino G., Naso A., Feltracco P., Carraro P., Basso S.M., Varotto S., et al. Cytokines and liver failure: modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated with molecular adsorbent recycling system (MARS). Acta Biomed 74 Suppl 2 (2003) 7-9
11. Guo L.M., Liu J.Y., Xu D.Z., Li B.S., Han H., Wang L.H., et al. Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int 23 Suppl 3 (2003) 16-20
12. Hirota M., Shibata M., and Ogawa M. Increased concentrations of plasma interleukin-18 in patients with hepatic failure 1 week after surgery. J Immunother (1997) 25 Suppl 1 (2002) S75-S77
13. Shinoda M., Wakabayashi G., Shimazu M., Saito H., Hoshino K., Tanabe M., et al. Increased serum and hepatic tissue levels of interleukin-18 in patients with fulminant hepatic failure. J Gastroenterol Hepatol 21 (2006) 1731-1736
14. Dinarello C.A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 27 (2007) 98-114
15. Tsutsui H., Matsui K., Okamura H., and Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev 174 (2000) 192-209
16. Creagh E.M., Conroy H., and Martin S.J. Caspase-activation pathways in apoptosis and immunity. Immunol Rev 193 (2003) 10-21
17. Chiang C.K., Huang J.W., Hsu S.P., Ho T.I., Pai M.F., Peng Y.S., et al. Plasma interleukin-18 levels in hemodialysis patients: increased by dialysis process and association with interleukin-6 and tumor necrotic factor-alpha. Blood Purif 24 (2006) 174-179
18. Stange J., Hassanein T.I., Mehta R., Mitzner S.R., and Bartlett R.H. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 26 (2002) 103-110
19. Faybik P., Bacher A., Kozek-Langenecker S.A., Steltzer H., Krenn C.G., Unger S., et al. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study. Crit Care 10 (2006) R24
20. Miyake Y., Iwasaki Y., Terada R., Takaguchi K., Sakaguchi K., Shiratori Y., et al. Systemic inflammatory response syndrome strongly affects the prognosis of patients with fulminant hepatitis B. J Gastroenterol 42 (2007) 485-492
21. Rolando N., Wade J., Davalos M., Wendon J., Philpott-Howard J., Williams R., et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology 32 (2000) 734-739
22. Shawcross D.L., Davies N.A., Williams R., and Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 40 (2004) 247-254
23. Tilg H., and Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343 (2000) 1467-1476
24. Nakae H., Zheng Y.J., Wada H., Tajimi K., and Endo S. Involvement of IL-18 and soluble fas in patients with postoperative hepatic failure. Eur Surg Res 35 (2003) 61-66
25. Yonekawa C., Nakae H., Tajimi K., and Asanuma Y. Effectiveness of combining plasma exchange and continuous hemodiafiltration in patients with postoperative liver failure. Artif Organs 29 (2005) 324-328
26. Tsutsui H., Matsui K., Kawada N., Hyodo Y., Hayashi N., Okamura H., et al. IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 159 (1997) 3961-3967
27. Mita A., Hashikura Y., Tagawa Y., Nakayama J., Kawakubo M., Miyagawa S., et al. Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Am J Gastroenterol 100 (2005) 2551-2559
28. Taieb J., Mathurin P., Poynard T., Gougerot-Pocidalo M.A., and Chollet-Martin S. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 351 (1998) 1930-1931
29. Sakao Y., Takeda K., Tsutsui H., Kaisho T., Nomura F., Okamura H., et al. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int Immunol 11 (1999) 471-480
30. Gu Y., Kuida K., Tsutsui H., Ku G., Hsiao K., Fleming M.A., et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275 (1997) 206-209
31. Adlbrecht C., Hoetzenecker K., Posch M., Steiner S., Kopp C., Hacker S., et al. Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction. Eur J Clin Invest 37 (2007) 372-380
32. Ankersmit H.J., Weber T., Auer J., Roth G., Brunner M., Kvas E., et al. Increased serum concentrations of soluble CD95/Fas and caspase 1/ICE in patients with acute angina. Heart 90 (2004) 151-154
33. Moser B., Roth G., Brunner M., Lilaj T., Deicher R., Wolner E., et al. Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: a comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. Biochem Biophys Res Commun 308 (2003) 581-585
34. Roth G., Moser B., Krenn C., Brunner M., Haisjackl M., Almer G., et al. Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance. Biochem Biophys Res Commun 308 (2003) 840-846
35. Rouquet N., Pages J.C., Molina T., Briand P., and Joulin V. ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Curr Biol 6 (1996) 1192-1195
36. Yoshida N., Iwata H., Yamada T., Sekino T., Matsuo H., Shirahashi K., et al. Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptosis by caspase inhibitor. J Gastroenterol Hepatol 22 (2007) 2015-2021
37. Ankersmit H.J., Deicher R., Moser B., Teufel I., Roth G., Gerlitz S., et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 125 (2001) 142-148
38. Ankersmit H.J., Tugulea S., Spanier T., Weinberg A.D., Artrip J.H., Burke E.M., et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 354 (1999) 550-555
39. Ilonen I., Koivusalo A.M., Hockerstedt K., and Isoniemi H. Albumin dialysis has no clear effect on cytokine levels in patients with life-threatening liver insufficiency. Transplant Proc 38 (2006) 3540-3543
40. Stadlbauer V., Krisper P., Aigner R., Haditsch B., Jung A., Lackner C., et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 10 (2006) R169
41. Shibata M., Hirota M., Nozawa F., Okabe A., Kurimoto M., Ogawa M., et al. Increased concentrations of plasma IL-18 in patients with hepatic dysfunction after hepatectomy. Cytokine 12 (2000) 1526-1530